Recently, the Lecanemab Injection (trade name: 乐意保/Leqembi) of Eisai Inc. was approved for marketing by China NMPA through the priority review and approval procedures. It is indicated for the treatment of mild cognitive impairment and dementia caused by Alzheimer's disease.

The accumulation of amyloid beta (Aβ) plaques in the brain is one of the typical pathophysiological features of Alzheimer's disease. Lecanemab Injection is a humanized immunoglobulin IgG1 monoclonal antibody that directly antagonizes aggregated soluble and insoluble Aβ, thereby reducing Aβ plaques. The marketing of this drug provides a new treatment option for patients with Alzheimer's disease.